BRAF and melanoma: The purpose of the project is to characterize the molecular landscape of a set of 28 malignant melanomas using next-generation sequencing, identify the prevalence and nature of class 3-5 variants (e.g., <i>NRAS</i>, <i>BRAF</i>, <i>KIT</i>, <i>TP53</i>), assess the genetic complexity and molecular patterns, and use these insights to inform personalized therapies and optimize patient stratification for potential combination strategies (targeted therapy followed by immunotherapy).